Crescent Biopharma, Inc. (CBIO)
(Delayed Data from NSDQ)
$11.60 USD
-0.24 (-2.03%)
Updated Aug 5, 2025 03:58 PM ET
After-Market: $11.57 -0.03 (-0.26%) 5:32 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CBIO 11.60 -0.24(-2.03%)
Will CBIO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CBIO based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for CBIO
Crescent Biopharma reports Q2 results
CBIO Financial Stability: Cash Reserves to Support Operations Through 2027
Crescent (CBIO) Completes Merger and Advances Cancer Therapeutics Initiative
Crescent Biopharma reports Q2 EPS ($4.93)